On the use of familial aggregation in population-based case probands for calculating penetrance.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of the National Cancer Institute

• Publication date

  2002-08-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JNCI/94.16.1221PMID 12189225
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

  2001cited by this paper
• A Marginal Likelihood Approach for Estimating Penetrance from Kin‐Cohort Designs

  2001cited by this paper
• The search for cancer risk factors: when can we stop looking?

  2001cited by this paper
• Effects of violations of assumptions on likelihood methods for estimating the penetrance of an autosomal dominant mutation from kin-cohort studies

  2001cited by this paper
• Genetic epidemiology of female breast cancer.

  2001cited by this paper
• Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

  2001cited by this paper
• Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases

  2000cited by this paper
• Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.

  2000cited by this paper
• Bias and efficiency in family-based gene-characterization studies: conditional, prospective, retrospective, and joint likelihoods.

  2000cited by this paper
• Risk models for familial ovarian and breast cancer

  2000cited by this paper
• Ascertainment adjustment: where does it take us?

  2000cited by this paper
• Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS).

  1999cited by this paper
• Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.

  1999cited by this paper
• Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

  1999cited by this paper
• Designing studies to estimate the penetrance of an identified autosomal dominant mutation: Cohort, case‐control, and genotyped‐proband designs

  1999cited by this paper
• Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.

  1999cited by this paper
• Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

  1998cited by this paper
• Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.

  1998cited by this paper
• A New Strategy for Evaluating the Impact of Epidemiologic Risk Factors for Cancer With Application to Melanoma.

  1998cited by this paper
• Population-based study of risk of breast cancer in carriers of BRCA2 mutation.

  1998cited by this paper
• The kin-cohort study for estimating penetrance.

  1998cited by this paper
• Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

  1998cited by this paper
• Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.

  1998cited by this paper
• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

  1997cited by this paper
• Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

  1997cited by this paper
• Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

  1996cited by this paper
• Scientific Basis of Health Services

  1996cited by this paper
• An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.

  1995cited by this paper
• Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1995cited by this paper
• 'Twixt cup and lip: how intractable is the ascertainment problem?

  1995cited by this paper
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1994cited by this paper
• A simple frailty model for family studies with covariates.

  1994cited by this paper
• Fundamentals of Genetic Epidemiology

  1993cited by this paper
• Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale.

  1992cited by this paper
• Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

  1989cited by this paper
• Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates

  1984cited by this paper
• Weighted distributions and size-biased sampling with applications to wildlife populations and human families

  1978cited by this paper
• A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix.

  1951cited by this paper

• How is familial idiopathic scoliosis transmitted? Analysis of 26 pedigrees.

  2025cites this paper
• One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them.

  2025cites this paper
• Peutz-Jeghers syndrome beyond the gastrointestinal tract: A case report on breast cancer

  2025cites this paper
• Breast cancer risk associated with BRCA1 and BRCA2 pathogenic variants in the Eastern Chinese population

  2024cites this paper
• First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants

  2022cites this paper
• Natural history of Huntington’s disease: evolution of modeling onset

  2022cites this paper
• Non‐parametric estimation of the age‐at‐onset distribution from a cross‐sectional sample

  2022cites this paper
• Penetrance estimation of PRRT2 variants in paroxysmal kinesigenic dyskinesia and infantile convulsions

  2021cites this paper
• Loss-of-Function FLNC Variants Are Associated With Arrhythmogenic Cardiomyopathy Phenotypes When Identified Through Exome Sequencing of a General Clinical Population

  2021cites this paper
• Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG)

  2021cites this paper
• Peutz–Jeghers Syndrome and the Role of Imaging: Pathophysiology, Diagnosis, and Associated Cancers

  2021cites this paper
• Evaluation of family health history collection methods impact on data and risk assessment outcomes

  2020cites this paper
• Management of Secondary Genomic Findings.

  2020cites this paper
• FEP Medical Policy Manual FEP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers

  2020cites this paper
• Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

  2020cites this paper
• Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

  2019cites this paper
• Contribution of Common Genetic Variants to Familial Aggregation of Disease and Implications for Sequencing Studies

  2019cites this paper
• Genetic Testing for Hereditary Breast and/or Ovarian Cancer-10/1/2018 (revised uploaded 2/14/2019)

  2019cites this paper
• Germline Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers

  2018cites this paper
• Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical Surveillance

  2018cites this paper
• Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?

  2018cites this paper
• Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome

  2018cites this paper
• Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome (BRCA1 or BRCA2)

  2018cites this paper
• Genetic Testing for Hereditary Breast and / or Ovarian Cancer Syndrome ( BRCA 1 or BRCA 2 ) Policy # 00047

  2017cites this paper
• Statistical modeling of Huntington disease onset.

  2017cites this paper
• Human genetics as a model for target validation: finding new therapies for diabetes

  2017cites this paper
• Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome

  2017cites this paper
• Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome

  2017cites this paper
• Ethical Considerations for the Return of Incidental Findings in Ophthalmic Genomic Research

  2016cites this paper
• Quantifying prion disease penetrance using large population control cohorts

  2016cites this paper
• Relevance of risk factors of breast cancer in women: An Eastern Indian scenario.

  2016cites this paper
• Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.

  2016cites this paper
• Aggregate penetrance of genomic variants for actionable disorders in European and African Americans

  2016cites this paper
• Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity.

  2016cites this paper
• Quantifying penetrance in a dominant disease gene using large population control cohorts

  2016cites this paper
• Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations

  2016cites this paper
• Association of Clinical Features With Incidental Findings From Exome Sequencing in 3,223 African Americans

  2015cites this paper
• Skin cancer risk in BRCA1/2 mutation carriers

  2015cites this paper
• Prognostic and Predictive Values and Statistical Interactions in the Era of Targeted Treatment

  2015cites this paper
• Analysis of multivariate failure times in the presence of selection bias with application to breast cancer

  2015cites this paper
• When is it MODY? Challenges in the Interpretation of Sequence Variants in MODY Genes.

  2015cites this paper
• Genetic Tests: Clinical Validity and Clinical Utility

  2014influential citation
• Breast-cancer risk in families with mutations in PALB2.

  2014cites this paper
• Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies

  2014cites this paper
• Breast-cancer risk in families with mutations in PALB2.

  2014cites this paper
• Genetic Testing for Hereditary Breast and / or Ovarian Cancer Policy

  2014cites this paper
• Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2

  2014cites this paper
• A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.

  2014cites this paper
• Whole Genome and Exome Sequencing of Type 2 Diabetes

  2014cites this paper
• Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.

  2014cites this paper
• COMBINING ISOTONIC REGRESSION AND EM ALGORITHM TO PREDICT GENETIC RISK UNDER MONOTONICITY CONSTRAINT.

  2014cites this paper
• Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

  2013cites this paper
• Studies to investigate a possible association between Polycystic Ovary Syndrome and Epithelial Ovarian Cancer

  2013cites this paper
• Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes

  2013cites this paper
• Increased Rate of Phenocopies in All Age Groups in BRCA1/BRCA2 Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to BRCA2 Mutation Carriers

  2013cites this paper
• Low penetrance of autosomal dominant lateral temporal epilepsy in Italian families without LGI1 mutations

  2013influential citation
• Recommendations for returning genomic incidental findings? We need to talk!

  2013cites this paper
• Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2

  2013cites this paper
• A Comprehensive Approach to the IT: Clinical Practice Interface

  2012cites this paper
• Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

  2012cites this paper
• Association between Contraceptive Pills with Breast Tumor in Indonesia

  2011cites this paper
• AN EM COMPOSITE LIKELIHOOD APPROACH FOR MULTISTAGE SAMPLING OF FAMILY DATA.

  2011influential citation
• Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.

  2011cites this paper
• Metaanaliza penetracji BRCA1 i BRCA2

  2011cites this paper
• "Getting on with it": New Zealand Women's Experiences of Living with an Increased Risk of Breast and Ovarian Cancer

  2011influential citation
• A strategy for distinguishing optimal cancer subtypes

  2011cites this paper
• HER receptor-mediated dynamic signalling in breast cancer cells

  2011cites this paper
• Ophira M. GinsburgCharmaine Kim-SingWilliam D. Foulkes • Parviz GhadirianHenry T. LynchPing SunSteven A. Narod • Hereditary Breast Cancer Clinical Study Group

  2010cites this paper
• Inheritance and the Risk of Breast Cancer

  2010cites this paper
• Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2

  2010cites this paper
• BRCA1 mutations and colorectal cancer in Poland

  2010cites this paper
• Genetic susceptibility to breast cancer

  2010cites this paper
• Chipping Away the ‘Missing Heritability’: GIANT Steps Forward in the Molecular Elucidation of Obesity – but Still Lots to Go

  2010cites this paper
• Estimating Disease Prevalence Using Relatives of Case and Control Probands

  2010cites this paper
• Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain)

  2010cites this paper
• Estimating gene penetrance from family data

  2010cites this paper
• Non‐parametric tests for right‐censored data with biased sampling

  2010cites this paper
• Efficient Nonparametric Estimation from Kin–Cohort Data

  2010influential citation
• BRCA1 and BRCA2 families and the risk of skin cancer

  2010cites this paper
• The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family

  2010cites this paper
• Hubungan Kontrasepsi Pil dengan Tumor/Kanker Payudara di Indonesia

  2009cites this paper
• Estimating the Absolute Risk of Disease Associated with Identified Mutations

  2009cites this paper
• Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: A call for evidence

  2009cites this paper
• Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers

  2009cites this paper
• Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband

  2009cites this paper
• Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: A call for dialogue

  2009cites this paper
• Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario

  2009cites this paper
• Variation of Breast Cancer Risk Among BRCA 1 / 2 Carriers : An Investigation by the WECARE Study Group

  2009cites this paper
• Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.

  2009cites this paper
• Being ‘at-risk’ for developing cancer: cognitive representations and psychological outcomes

  2009cites this paper
• Analyzing Length-Biased Data With Semiparametric Transformation and Accelerated Failure Time Models

  2009influential citation
• Age-dependent penetrance of different germline mutations in the BRCA1 gene

  2009cites this paper
• Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin

  2008cites this paper
• Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family

  2008cites this paper
• The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

  2008cites this paper
• Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method.

  2008cites this paper
• Tilting at Quixotic Trait Loci (QTL): An Evolutionary Perspective on Genetic Causation

  2008cites this paper
• Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies

  2008cites this paper
• Variation of breast cancer risk among BRCA1/2 carriers.

  2008cites this paper
• Penetrance of LGI1 mutations in autosomal dominant partial epilepsy with auditory features

  2008cites this paper